79 completed, 14 terminated, 10 recruiting, 7 active not recruiting. 119 Phase 2, 8 Phase 1, 5 Phase 3.
Follow Eczema: new trials by email Literature Review of Eczema trials Research Report on Eczema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis IMG-007 - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Enrolling by invitation | Inmagene LLC | 400 | 2026-06-05 | 2026-07-29 |
| A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis Camoteskimab, Placebo - Atopic Dermatitis, Atopic | Phase 2 | Recruiting | Apollo Therapeutics Ltd | 280 | 2026-05-28 | 2026-08-28 |
| Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD Soquelitinib, Placebo - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Recruiting | Corvus Pharmaceuticals, Inc. | 200 | 2026-02-01 | 2026-03-05 |
| A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema PF-08049820, Placebo - Atopic Dermatitis, Eczema, Atopic | Phase 2 | Recruiting | Pfizer | 165 | 2025-11-20 | 2026-10-13 |
| Phase 2b Study of EVO756 in Adults With Atopic Dermatitis EVO756, Placebo control - Atopic Dermatitis | Phase 2 | Completed | Evommune, Inc. | 121 | 2025-08-26 | 2026-10-05 |
| A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis BFB759, Placebo - Atopic Dermatitis (AD) | Phase 2 | Active not recruiting | Bluefin Biomedicine, Inc. | 225 | 2025-07-15 | 2026-07-30 |
| A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) GX-03, Vehicle - Eczema Atopic Dermatitis, Eczema | Phase 2 / Phase 3 | Recruiting | Turn Therapeutics | 190 | 2025-07-11 | 2026-09-04 |
| A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis IMG-007, Placebo - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Recruiting | Inmagene LLC | 405 | 2025-06-17 | 2026-08-12 |
| Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis ARQ-151 cream 0.05% - Atopic Dermatitis (Eczema) | Phase 2 | Completed | Arcutis Biotherapeutics, Inc. | 101 | 2025-06-09 | 2025-12-10 |
| ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis ATI-045, Placebo - Atopic Dermatitis, Atopic | Phase 2 | Active not recruiting | Aclaris Therapeutics, Inc. | 110 | 2025-05-30 | 2026-09-29 |
| Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis GHZ339, Placebo - Atopic Dermatitis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 224 | 2025-05-16 | 2026-09-28 |
| Efficacy of Topical Cannabidiol for Eczema Cannabidiol (CBD), Triamcinolone (TAC) 0.1% cream - Chronic Pruritus, Eczema | Phase 2 | Enrolling by invitation | Khon Kaen University | 60 | 2025-05-01 | 2026-08-04 |
| Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. zabalafin - Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema | Phase 2 | Recruiting | Alphyn Biologics | 72 | 2025-03-25 | 2025-08-01 |
| Herbal Ointment in Treating Atopic Dermatitis Topically herbal ointment, Placebo - Atopic Dermatitis, Atopic Dermatitis (AD) | Phase 2 / Phase 3 | Recruiting | En Chu Kong Hospital | 66 | 2025-03-01 | 2025-02-27 |
| Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis EVO301, Placebo - Atopic Dermatitis (AD), Eczema | Phase 2 | Completed | Evommune, Inc. | 71 | 2025-02-13 | 2025-12-04 |
| A Study of Barzolvolimab in Patients With Atopic Dermatitis Barzolvolimab, Matching placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Celldex Therapeutics | 131 | 2024-12-18 | 2026-08-11 |
| LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema) Lactobacillus Paracasei LPB27, Maltodextrin - Eczema, Allergy | Phase 2 | Unknown | The University of New South Wales | 100 | 2024-11-15 | 2025-06-03 |
| Cardamom and Topical Roseomonas in Atopic Dermatitis Roseomonas mucosa (RSM2015) and Cardamom seeds, Placebo (sucrose) - Atopic Dermatitis, Eczema | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 120 | 2024-10-09 | 2026-10-30 |
| Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis ATI-2138 - Atopic Dermatitis | Phase 2 | Completed | Aclaris Therapeutics, Inc. | 14 | 2024-08-19 | 2026-03-12 |
| Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. GSK1070806, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | GlaxoSmithKline | 79 | 2024-06-05 | 2026-06-16 |
Showing 20 of 119. Sign in to see all of them.
Dermatitis, Atopic (98) · Dermatitis (24) · Skin Diseases (19) · Pruritus (12) · Immune System Diseases (9) · Skin Diseases, Eczematous (6) · Hypersensitivity (5) · Psoriasis (5) · Food Hypersensitivity (4) · Skin Diseases, Genetic (4) · Asthma (3) · Inflammation (3) · Dermatitis, Allergic Contact (2) · Egg Hypersensitivity (2)
Skin and Connective Tissue Diseases (119) · Skin Diseases, Eczematous (113) · Hypersensitivity, Immediate (101) · Skin Diseases (100) · Hypersensitivity (99) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (98) · Genetic Diseases, Inborn (97) · Dermatitis (95) · Immune System Diseases (95) · Skin Diseases, Genetic (94) · Pathological Conditions, Signs and Symptoms (15) · Signs and Symptoms (12) · Skin Manifestations (12) · Skin Diseases, Papulosquamous (6) · Bronchial Diseases (3)
R-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-(((2-methyl-5-quinolyl)amino)methyl)pentan-2-ol (3) · dupilumab (3) · gusacitinib (3) · Exercise (2) · GSK1070806 (2) · Probiotics (2) · Triamcinolone (2) · Ustekinumab (2) · abrocitinib (2) · apremilast (2) · tezepelumab (2) · 4-(4-(aminomethyl)-7a-methyl-1-methylideneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexan-1-ol (1) · ADX-629 (1) · AK002 (1) · BID protein, human (1)
Pfizer (7) · Novartis Pharmaceuticals (5) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Asana BioSciences (3) · Bayer (3) · GlaxoSmithKline (3) · Inmagene LLC (3) · Regeneron Pharmaceuticals (3) · ASLAN Pharmaceuticals (2) · Aclaris Therapeutics, Inc. (2) · Apollo Therapeutics Ltd (2) · Eli Lilly and Company (2) · Evelo Biosciences, Inc. (2) · Evommune, Inc. (2) · Forte Biosciences, Inc. (2)
United States (77) · Canada (47) · Germany (29) · Poland (25) · Japan (17) · Czechia (16) · Australia (15) · United Kingdom (13) · Spain (11) · Hungary (10) · Bulgaria (8) · China (7) · France (6) · New Zealand (6) · Taiwan (6)
David Zammit, Ph.D. (3) · Dr Lynette Shek, Consultant (2) · Gideon Lack, MD (2) · Melissa Magliocco, MD (2) · Ajay Aggarwal, MD (1) · Akiko Yagami, MD, PhD (1) · Alice B. Gottlieb, M.D., PhD. (1) · Alicia Barba, MD (1)
PMID 16205524, PMID 17346444, PMID 17349686, PMID 18221472, PMID 19525871, PMID 21801246, PMID 22153774, PMID 23174658, PMID 23517039, PMID 23768574, PMID 23902407, PMID 23926244, PMID 24330256, PMID 24948349, PMID 25002964, PMID 25705822, PMID 25705823, PMID 26454361, PMID 26569624, PMID 26618557, PMID 26777100, PMID 26942922, PMID 27268421, PMID 27297994, PMID 29567358, PMID 30556911, PMID 31419544, PMID 31595499, PMID 31629805, PMID 32101256, PMID 33165005, PMID 33982267, PMID 35567671, PMID 35986664, PMID 36116481, PMID 36509097, PMID 36521802, PMID 36529811, PMID 36723913, PMID 36800177, PMID 37480432, PMID 38194047, PMID 38267692, PMID 38363461, PMID 38743155, PMID 38946973, PMID 39018038, PMID 39039395, PMID 39234416, PMID 39470878
2018 (4), 2023 (3), 2016 (1), 2019 (1), 2025 (1), R33AR077495 (1), U01AI147462 (1)